CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of hepatobiliary cancers.
  
  LEARNING OBJECTIVES

  • Recall recently presented clinical trial results with anti-PD-L1 antibody therapy in combination with anti-VEGF therapy for patients with hepatocellular carcinoma (HCC) and a high risk of recurrence after curative resection or ablation or those receiving transarterial chemoembolization for unresectable disease, and consider the potential role of these strategies in clinical practice.
  • Appreciate available and recently updated Phase III data with novel first-line treatment strategies for unresectable or metastatic HCC, and discuss how these regimens can be optimally integrated into patient care.
  • Evaluate the rationale for and available data with the use of anti-PD-1/PD-L1 antibodies in combination with anti-CTLA-4 antibodies for patients with previously untreated HCC to determine the current role of these novel regimens.
  • Discuss the biological justification for the evaluation of immune checkpoint inhibitors for advanced biliary tract cancers, and develop strategies to optimally incorporate anti-PD-1/PD-L1 antibody-based approaches into the care of patients with these diseases.
  • Assess key data sets supporting the FDA approvals of fibroblast growth factor receptor (FGFR) inhibitors for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or other rearrangement to optimally select and sequence these agents.
  • Evaluate available clinical trial findings with HER2-directed therapies for HER2-positive biliary tract cancers, and contemplate the current and future role of these agents or regimens for appropriately selected patients.
  • Recall available and emerging data with investigational agents and strategies currently in clinical testing for HCC and biliary tract cancers, and as applicable, refer eligible patients for trial participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Video Program: Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.
  
  AMERICAN BOARD OF SURGERY (ABS) — CONTINUOUS CERTIFICATION (CC)
  Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.
  
  Please note, these programs have been specifically designed for the following ABS practice area: complex general surgical oncology.
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ASCO2024/Hepatobiliary/Video/CME.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Edward Kim, MD
  Director, Interventional Oncology
  Professor of Radiology and Surgery
  Division of Interventional Radiology
  Mount Sinai Health System
  New York, New York
  
  No relevant conflicts of interest to disclose.
  
  Arndt Vogel, MD, PhD
  Professor of Medicine, University of Toronto
  Longo Family Chair in Liver Cancer Research
  Division of Gastroenterology and Hepatology
  Toronto General Hospital
  Medical Oncology
  Princess Margaret Cancer Centre
  Toronto General Hospital Research Institute
  Schwartz Reisman Liver Research Centre
  Toronto, Ontario, Canada
  
  Consultancy and Advisory; Speaker: Amgen Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Boehringer Mannheim, Bristol Myers Squibb, Eisai Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, MSD, Pierre Fabre, Roche Laboratories Inc, Servier Pharmaceuticals LLC, Taiho Oncology Inc.
  
  MODERATOR
  Robin K (Katie) Kelley, MD
  Professor of Clinical Medicine, Division of Hematology/Oncology
  Helen Diller Family Comprehensive Cancer Center
  University of California, San Francisco (UCSF)
  San Francisco, California
  
  Advisory Committees (Payments to Institution): Agios Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Exelixis Inc, Ipsen Biopharmaceuticals Inc, Merck; Consulting Agreements (Payments to Self): Compass Therapeutics, Exact Sciences Corporation, GSK, J-Pharma Co Ltd, Kinnate Biopharma, Moderna, Regeneron Pharmaceuticals Inc, Tyra Biosciences; Contracted Research (Payment to Institution for Trial Conduct): Agios Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Compass Therapeutics, EMD Serono Inc, Exelixis Inc, Genentech, a member of the Roche Group, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Partner Therapeutics, QED Therapeutics, Servier Pharmaceuticals LLC, Surface Oncology, Taiho Oncology Inc, Tyra Biosciences; Independent Data Monitoring Committees (Unpaid Service): Genentech, a member of the Roche Group, Merck.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Incyte Corporation, Jazz Pharmaceuticals Inc, and Taiho Oncology Inc.
  
  Release date: June 2024
  Expiration date: June 2025
  
  After completing the post-test, learners may download and review the answers here in order to identify further areas of study.